SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Vaccines Année : 2021

SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center

Résumé

Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis.
Fichier principal
Vignette du fichier
vaccines-09-00560-v2.pdf (439.2 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-03641471 , version 1 (14-04-2022)

Licence

Paternité

Identifiants

Citer

Luciana Kase Tanno, Frédéric Berard, Etienne Beaudoin, Alain Didier, Pascal Demoly. SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center. Vaccines, 2021, 9 (6), pp.560. ⟨10.3390/vaccines9060560⟩. ⟨hal-03641471⟩
87 Consultations
56 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More